<DOC>
	<DOCNO>NCT00446199</DOCNO>
	<brief_summary>The purpose study determine low effective dose study drug relief moderate severe vasomotor symptom postmenopausal woman 12 week .</brief_summary>
	<brief_title>Low-dose Hormone Therapy Relief Vasomotor Symptoms</brief_title>
	<detailed_description>This study previously post Berlex , Inc. Berlex , Inc. rename Bayer HealthCare Pharmaceuticals , Inc. Bayer HealthCare Pharmaceuticals , Inc. sponsor trial .</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Postmenopausal woman &gt; 40 year age experience minimum 7 8 moderate severe hot flush per day 50 60 moderate severe hot flush per week The usual exclusion criterion hormone therapy apply Intake medication hormone affect hot flush</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Vasomotor symptom relief</keyword>
	<keyword>Postmenopausal woman</keyword>
	<keyword>Severe Moderate Vasomotor symptom</keyword>
</DOC>